Form 4: SERA CSO Sells Shares for Tax Obligations

SERA Prognostics' Chief Scientific Officer, John J. Boniface, sold 1,332 shares of Class A Common Stock at a weighted average price of $3.31 to cover tax withholding obligations.

Summary

• John J. Boniface, Chief Scientific Officer of SERA Prognostics, Inc., reported a transaction involving Class A Common Stock.
• On December 10, 2025, Boniface sold 1,332 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $3.31 per share, with individual transactions ranging from $3.28 to $3.38.
• This transaction was a 'sell to cover' to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs), mandated by the issuer.
• The sale does not represent a discretionary transaction by Boniface.
• Following this transaction, Boniface beneficially owns 150,397 shares of Class A Common Stock.
• This total includes 3 shares purchased through the Sera Prognostics, Inc. 2021 Employee Stock Purchase Plan (ESPP) for the purchase period of June 2, 2025 to November 28, 2025.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The transaction is a non-discretionary 'sell to cover' for tax purposes, which is a neutral event. The insider still holds a substantial number of shares and participated in the ESPP, indicating continued alignment. The slight negative is the reduction in direct holdings, but it is offset by the mandatory nature.

Positives

• The transaction was non-discretionary, indicating it was a mandatory 'sell to cover' for tax obligations rather than a voluntary sale by the officer.
• The officer still retains a significant beneficial ownership of 150,397 shares, demonstrating continued alignment with shareholder interests.
• The officer also acquired 3 shares through the Employee Stock Purchase Plan, indicating ongoing participation in company equity programs.

Negatives

• A sale of shares by an insider, even if for tax purposes, reduces their direct equity stake in the company.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is a transactional report for an insider.

Management Comments

• The sale was mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by 'sell to cover' transactions and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, specifically a 'sell to cover' for tax purposes. Such transactions are common across industries when restricted stock units vest, and they typically do not reflect a change in management's outlook on the company's prospects. The use of a 10b5-1 plan indicates pre-planned transactions to avoid accusations of insider trading.

Comparison to Industry Standards

• The 'sell to cover' mechanism for tax withholding is a standard practice in many publicly traded companies across various industries, including biotechnology and diagnostics, where equity compensation like RSUs is prevalent. This transaction aligns with typical corporate governance practices for managing executive compensation and tax liabilities. No specific comparable companies or projects are mentioned in this transactional filing.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but the non-discretionary nature mitigates negative sentiment. The continued substantial holding and ESPP participation suggest ongoing insider confidence.
• Employees: The transaction relates to equity compensation (RSUs) and an Employee Stock Purchase Plan (ESPP), indicating standard employee benefit programs are in place.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell to cover' transaction by a Chief Scientific Officer to satisfy tax obligations related to RSU vesting. Such sales are common and typically do not signal a change in management's view of the company's prospects. The officer retains a significant equity stake and participated in the ESPP, suggesting continued alignment. Therefore, this specific filing alone does not provide a basis for a 'buy' or 'sell' recommendation, maintaining a 'hold' position based solely on this information.

Keywords

SERA Prognostics, SERA, Form 4, Insider Trading, Stock Sale, Chief Scientific Officer, John J. Boniface, Restricted Stock Units, Tax Withholding, Equity Compensation, 10b5-1 Plan